<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620282</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1799</org_study_id>
    <nct_id>NCT00620282</nct_id>
  </id_info>
  <brief_title>The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). The purpose of the trial is to
      assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who
      are on diet and lifestyle changes or treated with metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (Glycosylated Haemoglobin A1c)</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Percentage point change in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Change in FPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>week 0, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile - Change in Total Cholesterol (TC)</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Change in TC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile - Change in LDL-C</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Change in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile - Change in HDL-C</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Change in HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipid Profile - Change in Triglycerides (TG)</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Change in TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of Cardiovascular Risk - Change in TNF-alpha</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Change in TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range</measure>
    <time_frame>week 0, week 12</time_frame>
    <description>Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycaemic Episodes</measure>
    <time_frame>weeks 0-12</time_frame>
    <description>Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Lira 1.8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Stepwise dose increase, s.c. (under the skin) injection, once daily</description>
    <arm_group_label>Lira 1.8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>Tablets, 1 - 4 mg daily</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Diet and lifestyle changes or metformin monotherapy for at least three months

          -  HbA1c (glycosylated haemoglobin) 6.5-9.0% (both inclusive)

          -  Body Mass Index (BMI) less than or equal to 40 kg/m^2

        Exclusion Criteria:

          -  Previous treatment with insulin (except for short term treatment with insulin in
             connection with intercurrent illness, at the discretion of the Investigator)

          -  Previous treatment with glucagon-like peptide-1 (GLP-1) analogues/mimetics, including
             treatment in a clinical trial

          -  Treatment with any oral hypoglycaemic agents other than metformin in a period of 3
             months prior to screening

          -  Current smoker or history of smoking within 6 months prior to screening

          -  Evidence of overt cardiovascular disease (documented coronary heart disease, class
             II-IV congestive heart failure, cerebrovascular disease, or peripheral vascular
             disease)

          -  Abnormal, clinically significant exercise stress electrocardiogram (ECG) test, as
             judged by the Investigator

          -  Known retinopathy or maculopathy requiring acute treatment, as judged by the
             Investigator

          -  Known autonomic neuropathy, as judged by the Investigator

          -  Initiation or change (dose or treatment regimen) in concomitant blood
             pressure-lowering or lipid-lowering medication within 4 weeks prior to screening

          -  Systolic blood pressure more than or equal to 140 mmHg and/or diastolic blood pressure
             more than or equal to 90 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. doi: 10.1016/j.diabres.2012.09.008. Epub 2012 Sep 23.</citation>
    <PMID>23010561</PMID>
  </results_reference>
  <results_reference>
    <citation>Nandy D, Johnson C, Basu R, Joyner M, Brett J, Svendsen CB, Basu A. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diab Vasc Dis Res. 2014 Nov;11(6):419-30. doi: 10.1177/1479164114547358. Epub 2014 Sep 11.</citation>
    <PMID>25212693</PMID>
  </results_reference>
  <results_reference>
    <citation>Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Review. Erratum in: Diabetes Care. 2015 Aug;38(8):1622.</citation>
    <PMID>25504028</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>May 19, 2011</results_first_submitted>
  <results_first_submitted_qc>May 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 15, 2011</results_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at one site in the United States of America (USA).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lira 1.8</title>
          <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
        </group>
        <group group_id="P3">
          <title>Glimepiride</title>
          <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Arterial line unable to be placed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lira 1.8</title>
          <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
        </group>
        <group group_id="B3">
          <title>Glimepiride</title>
          <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="9.0"/>
                    <measurement group_id="B2" value="60.3" spread="7.3"/>
                    <measurement group_id="B3" value="57.7" spread="5.3"/>
                    <measurement group_id="B4" value="58.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="4.1"/>
                    <measurement group_id="B2" value="8.4" spread="4.6"/>
                    <measurement group_id="B3" value="6.8" spread="8.1"/>
                    <measurement group_id="B4" value="6.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Anti-diabetic Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diet/Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="4.5"/>
                    <measurement group_id="B2" value="31.6" spread="4.2"/>
                    <measurement group_id="B3" value="31.1" spread="4.9"/>
                    <measurement group_id="B4" value="31.8" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.09" spread="13.12"/>
                    <measurement group_id="B2" value="90.63" spread="13.47"/>
                    <measurement group_id="B3" value="91.99" spread="13.97"/>
                    <measurement group_id="B4" value="92.56" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Haemoglobin A1c (HbA1c)</title>
          <units>percentage of total haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="0.5"/>
                    <measurement group_id="B2" value="7.0" spread="0.5"/>
                    <measurement group_id="B3" value="7.3" spread="0.5"/>
                    <measurement group_id="B4" value="7.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Plasma Glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160.8" spread="31.2"/>
                    <measurement group_id="B2" value="145.2" spread="20.1"/>
                    <measurement group_id="B3" value="163.3" spread="33.3"/>
                    <measurement group_id="B4" value="156.6" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol (TC)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.2" spread="34.4"/>
                    <measurement group_id="B2" value="157.5" spread="32.0"/>
                    <measurement group_id="B3" value="160.2" spread="24.1"/>
                    <measurement group_id="B4" value="162.6" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low density lipoprotein (LDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102.8" spread="31.3"/>
                    <measurement group_id="B2" value="92.5" spread="23.5"/>
                    <measurement group_id="B3" value="94.1" spread="18.4"/>
                    <measurement group_id="B4" value="96.4" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High density lipoprotein (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="10.0"/>
                    <measurement group_id="B2" value="39.2" spread="7.5"/>
                    <measurement group_id="B3" value="43.5" spread="10.3"/>
                    <measurement group_id="B4" value="40.8" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides (TG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.8" spread="72.9"/>
                    <measurement group_id="B2" value="145.9" spread="57.5"/>
                    <measurement group_id="B3" value="141.4" spread="67.4"/>
                    <measurement group_id="B4" value="150.8" spread="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor necrosis factor-alpha (TNF-alpha)</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="1.5"/>
                    <measurement group_id="B2" value="1.4" spread="0.8"/>
                    <measurement group_id="B3" value="1.4" spread="0.5"/>
                    <measurement group_id="B4" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)</title>
        <description>Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)</title>
          <description>Assessed endothelial function by measuring the change in ACh-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mL/100 mL/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.244" spread="2.551"/>
                    <measurement group_id="O2" value="-3.187" spread="2.758"/>
                    <measurement group_id="O3" value="2.164" spread="2.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Ach-mediated FBF from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FBF as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0549</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>7.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.164</ci_lower_limit>
            <ci_upper_limit>15.025</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Ach-mediated FBF from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FBF as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5681</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>2.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.215</ci_lower_limit>
            <ci_upper_limit>9.375</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Ach-mediated FBF from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FBF as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1668</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>5.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.323</ci_lower_limit>
            <ci_upper_limit>13.024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)</title>
        <description>Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sodium Nitroprusside (SNP)-Mediated Forearm Blood Flow (FBF)</title>
          <description>Assessed endothelial function by measuring the change in SNP-mediated FBF at euglycemia (90 mg/dL) using forearm venous occlusion plethysmography (VOP) technique. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mL/100 mL/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.455" spread="2.681"/>
                    <measurement group_id="O2" value="-1.044" spread="2.893"/>
                    <measurement group_id="O3" value="2.746" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in SNP-mediated FBF from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FBF as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2648</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>4.499</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.535</ci_lower_limit>
            <ci_upper_limit>12.534</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in SNP-mediated FBF from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FBF as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8518</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>0.709</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.904</ci_lower_limit>
            <ci_upper_limit>8.322</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in SNP-mediated FBF from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FBF as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3435</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>3.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.194</ci_lower_limit>
            <ci_upper_limit>11.774</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c (Glycosylated Haemoglobin A1c)</title>
        <description>Percentage point change in HbA1c</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c (Glycosylated Haemoglobin A1c)</title>
          <description>Percentage point change in HbA1c</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>percentage of total haemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.629" spread="0.109"/>
                    <measurement group_id="O2" value="-0.094" spread="0.121"/>
                    <measurement group_id="O3" value="-0.552" spread="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.536</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.868</ci_lower_limit>
            <ci_upper_limit>-0.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6207</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.077</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.391</ci_lower_limit>
            <ci_upper_limit>0.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in HbA1c from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0098</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.458</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>-0.116</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG)</title>
        <description>Change in FPG</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG)</title>
          <description>Change in FPG</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.672" spread="3.643"/>
                    <measurement group_id="O2" value="-6.067" spread="4.079"/>
                    <measurement group_id="O3" value="-32.019" spread="3.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in FPG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean</param_type>
            <param_value>-35.605</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-46.797</ci_lower_limit>
            <ci_upper_limit>-24.413</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in FPG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0677</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-9.653</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.041</ci_lower_limit>
            <ci_upper_limit>0.736</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in FPG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline FPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean</param_type>
            <param_value>-25.952</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-37.429</ci_lower_limit>
            <ci_upper_limit>-14.475</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles</title>
        <description>The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime.</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Postprandial Glucose (PPG) Based on Self-measured 7-point Plasma Glucose Profiles</title>
          <description>The 7-point profile included plasma glucose measurements at the following time points: before each main meal (breakfast, lunch and dinner), 90 minutes after the start of each main meal (breakfast, lunch and dinner) and at bedtime.</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.175" spread="9.104"/>
                    <measurement group_id="O2" value="-20.304" spread="10.619"/>
                    <measurement group_id="O3" value="-35.99" spread="8.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PPG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline PPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4121</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-11.871</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-40.943</ci_lower_limit>
            <ci_upper_limit>17.201</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in PPG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline PPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7622</p_value>
            <p_value_desc>2-sided significance level of 5%</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>3.815</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.618</ci_lower_limit>
            <ci_upper_limit>29.247</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in PPG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline PPG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2651</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-15.686</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-43.838</ci_lower_limit>
            <ci_upper_limit>12.466</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.821" spread="0.455"/>
                    <measurement group_id="O2" value="-0.293" spread="0.486"/>
                    <measurement group_id="O3" value="1.038" spread="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline body weight as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0268</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-1.528</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.873</ci_lower_limit>
            <ci_upper_limit>-0.184</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline body weight as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean</param_type>
            <param_value>-2.859</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.139</ci_lower_limit>
            <ci_upper_limit>-1.579</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in body weight from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline body weight as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0486</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>1.331</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0090</ci_lower_limit>
            <ci_upper_limit>2.653</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile - Change in Total Cholesterol (TC)</title>
        <description>Change in TC</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile - Change in Total Cholesterol (TC)</title>
          <description>Change in TC</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.006" spread="5.274"/>
                    <measurement group_id="O2" value="4.243" spread="5.597"/>
                    <measurement group_id="O3" value="0.094" spread="5.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in TC from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7736</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-2.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.829</ci_lower_limit>
            <ci_upper_limit>13.354</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in TC from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7993</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>1.912</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-13.168</ci_lower_limit>
            <ci_upper_limit>16.991</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in TC from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TC as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5903</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-4.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.582</ci_lower_limit>
            <ci_upper_limit>11.284</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile - Change in LDL-C</title>
        <description>Change in LDL-C</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile - Change in LDL-C</title>
          <description>Change in LDL-C</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.243" spread="4.294"/>
                    <measurement group_id="O2" value="-2.459" spread="4.551"/>
                    <measurement group_id="O3" value="-1.529" spread="4.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in LDL-C from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline LDL-C as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5583</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>3.702</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.96</ci_lower_limit>
            <ci_upper_limit>16.365</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in LDL-C from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline LDL-C as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6517</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>2.773</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.537</ci_lower_limit>
            <ci_upper_limit>15.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in LDL-C from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline LDL-C as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8822</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>0.929</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.646</ci_lower_limit>
            <ci_upper_limit>13.505</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile - Change in HDL-C</title>
        <description>Change in HDL-C</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile - Change in HDL-C</title>
          <description>Change in HDL-C</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.393" spread="1.053"/>
                    <measurement group_id="O2" value="0.562" spread="1.133"/>
                    <measurement group_id="O3" value="1.116" spread="1.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in HDL-C from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HDL-C as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9131</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.169</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.273</ci_lower_limit>
            <ci_upper_limit>2.935</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in HDL-C from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HDL-C as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6362</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.723</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.785</ci_lower_limit>
            <ci_upper_limit>2.339</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in HDL-C from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline HDL-C as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7283</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>0.554</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.643</ci_lower_limit>
            <ci_upper_limit>3.751</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipid Profile - Change in Triglycerides (TG)</title>
        <description>Change in TG</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipid Profile - Change in Triglycerides (TG)</title>
          <description>Change in TG</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.163" spread="13.471"/>
                    <measurement group_id="O2" value="28.546" spread="14.282"/>
                    <measurement group_id="O3" value="-4.377" spread="13.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in TG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0694</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-36.709</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-76.467</ci_lower_limit>
            <ci_upper_limit>3.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in TG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-3.786</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-42.373</ci_lower_limit>
            <ci_upper_limit>34.801</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in TG from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TG as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0994</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-32.923</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-72.353</ci_lower_limit>
            <ci_upper_limit>6.507</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers of Cardiovascular Risk - Change in TNF-alpha</title>
        <description>Change in TNF-alpha</description>
        <time_frame>week 0, week 12</time_frame>
        <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers of Cardiovascular Risk - Change in TNF-alpha</title>
          <description>Change in TNF-alpha</description>
          <population>The ANCOVA full analysis set (FAS) includes all randomised subjects for whom data points could be collected at end of trial.</population>
          <units>pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.232"/>
                    <measurement group_id="O2" value="0.397" spread="0.25"/>
                    <measurement group_id="O3" value="-0.0050" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in TNF-alpha from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TNF-alpha as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2282</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.118</ci_lower_limit>
            <ci_upper_limit>0.278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in TNF-alpha from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TNF-alpha as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9569</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.018</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.697</ci_lower_limit>
            <ci_upper_limit>0.661</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in TNF-alpha from baseline to end of treatment at 12 weeks was analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline TNF-alpha as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2465</p_value>
            <p_value_desc>2-sided significance level of 5%.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least squares mean</param_type>
            <param_value>-0.402</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.097</ci_lower_limit>
            <ci_upper_limit>0.293</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range</title>
        <description>Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL).</description>
        <time_frame>week 0, week 12</time_frame>
        <population>Safety population included all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology and Biochemistry Tests - Number of Subjects With Blood Urea Nitrogen (BUN) Values Outside Reference Range</title>
          <description>Number of subjects with serum BUN values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 6.000 mg/dL, upper value 21.000 mg/dL) Male (lower value 8.000 mg/dL, upper value 25.000 mg/dL).</description>
          <population>Safety population included all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range</title>
        <description>Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL).</description>
        <time_frame>week 0, week 12</time_frame>
        <population>Safety population included all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Haematology and Biochemistry Tests - Number of Subjects With Creatinine Values Outside Reference Range</title>
          <description>Number of subjects with serum creatinine values outside reference range at Week 0 and Week 12, respectively. Reference range: Female (lower value 0.600 mg/dL, upper value 1.100 mg/dL) Male (lower value 0.800 mg/dL, upper value 1.300 mg/dL).</description>
          <population>Safety population included all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycaemic Episodes</title>
        <description>Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.</description>
        <time_frame>weeks 0-12</time_frame>
        <population>Safety population included all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lira 1.8</title>
            <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Glimepiride</title>
            <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycaemic Episodes</title>
          <description>Total number of hypoglycaemic episodes occurring from week 0 to week 12. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself and either plasma glucose was below 56 mg/dL or symptoms were reversed after food intake or glucagon/intravenous glucose administration. Minor if subject was able to treat her/himself and plasma glucose was below 56 mg/dL. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 56 mg/dL.</description>
          <population>Safety population included all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptoms Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse events were collected from week 0 to week 12.</time_frame>
      <desc>The full safety analysis set is all subjects exposed to at least one dose of the drug or who underwent at least one venous occlusion plethysmography (VOP) procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lira 1.8</title>
          <description>Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)</description>
        </group>
        <group group_id="E3">
          <title>Glimepiride</title>
          <description>Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Parotid Duct Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Muscle Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Snoring</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rash Maculo-Papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Novo Nordisk reserves the right to not release data until specified milestones (e.g. when clinical trial report is available), including right to not release interim results because such action can invalidate results of the entire trial. At trial end, one or more manuscripts for publication will be prepared collaboratively between Investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for less than 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

